Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2016-12-20
|
OPN-305 |
second-line lower (Low and intermediate-1) risk myelodysplastic syndrome |
1-2 |
Opsona Therapeutics (Ireland) |
Cancer - Oncology |
2016-12-20
|
GLPG1837 |
cystic fibrosis with the G551D mutation |
2 |
Galapagos (Belgium) |
Rare diseases - Genetic diseases |
2016-12-19
|
volanesorsen (phosphorothioate oligonucleotide targeted to apolipoprotein C-III - IONIS-APOCIIIRx) |
hypertriglyceridemia |
3 |
Akcea Therapeutics (USA - CA), a subsidiary of Ionis Pharmaceuticals (USA - CA) |
Metabolic diseases |
2016-12-18
|
LOXO- 101 (larotrectinib - (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate) |
adult solid tumors |
1 |
Loxo Oncology (USA - CT) |
Cancer - Oncology |
2016-12-16
|
BGB324 |
acute myeloid leukaemia |
1b-2 |
BerGenBio (Norway) |
Cancer - Oncology |
2016-12-16
|
BioChaperone Lispro® |
type 1 diabetes mellitus |
1 |
Adocia (France) Eli Lilly (USA - IN) |
Metabolic diseases |
2016-12-16
|
TG-1101 (ublituximab) and ibrutinib |
chronic lymphocytic leukemia (CLL) |
2 |
TG Therapeutics (USA - NY) |
Cancer - Oncology |
2016-12-14
|
NeuVax™ (nelipepimut-S) |
ductal breast carcinoma in situ |
2 |
Galena Biopharma (USA - OR) |
Cancer - Oncology |
2016-12-14
|
MIV-323 |
Respiratory Syncytial Virus (RSV) infection |
|
Medivir (Sweden) |
Infectious diseases |
2016-12-13
|
GTL001/ProCervix® |
treatment of adult women already infected with human papillomavirus (HPV) genotype 16 or 18 |
2 |
Genticel (France) |
Infectious diseases |
2016-12-13
|
Sollpura™ (liprotamase) |
cystic fibrosis |
|
Anthera Pharmaceuticals (USA - CA) |
Rare diseases - Genetic diseases |
2016-12-13
|
RHB-104 (clarithromycin, clofazimine and rifabutin) |
Crohn's disease |
3 |
RedHill Biopharma (Israel) |
Autoimmune diseases - Inflammatory diseases - Digestive diseases |
2016-12-13
|
MOR208 and idelalisib |
relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) |
2 |
MorphoSys (Germany) |
Cancer - Oncology |
2016-12-13
|
dasiglucagon (ZP4207) |
type 1 diabetes |
2 |
Zealand Pharma (Denmark) |
Metabolic diseases |
2016-12-12
|
pegpleranib in combination with Lucentis® (ranibizumab) |
neovascular age-related macular degeneration |
3 |
Novartis (Switzerland) |
Ophtalmological diseases |
2016-12-12
|
ATA 129 (EBV-CTL) |
rituximab-refractory EBV-Associated Post Transplant Lymphoproliferative Disorder (EBV-PTLD) |
3 |
Atara Biotherapeutics (USA - CA) |
Infectious diseases - Transplantation |
2016-12-12
|
GLPG0634 (filgotinib) |
Crohn's disease |
2 |
Galapagos (Belgium) AbbVie (USA - IL) |
Autoimmune diseases - Inflammatory diseases - Digestive diseases |
2016-12-12
|
C16G2 |
dental caries |
2 |
C3J Therapeutics (USA - CA) |
Infectious diseases |
2016-12-12
|
BMN 111 (vosoritide) |
achondroplasia |
3 |
Biomarin Pharmaceutical (USA - CA) |
Rare diseases - Genetic diseases |
2016-12-10
|
ABX464 |
HIV/Aids |
preclinical |
Abivax (France) |
Infectious diseases |